22 December 2025VideosAmericasMicheal Hebert, Greenberg Traurig | Chuck Sholtz, Verdiva Bio | Josh Mack, Halozyme | Lawrence Rozsnyai, Metsera

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSPN Awards USA: Meet the judges

10 April 2026 The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.

Americas

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

1 April 2026 After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.

Americas

Mylan withdraws defence claims against Novo in Wegovy dispute

13 March 2026 A proposed judgment by the rivals would extend the period in which Mylan is barred from obtaining regulatory approval for its generic of the weight-loss injectable.

More features

Litigator from Brown Rudnick moves firms to chair practice

Penile implant maker’s $17m trade secret award unravels

Appeals court eases Teva’s headache with reversal

Cancer drug researcher hit with suit over mutation-targeting tools

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Court narrows Mylan’s Copaxone suit but key claims survive

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

LSPN Awards USA: Meet the judges

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

More on this story

Editor's picks

Editor's picks

More features